Veterinary Dermatology Drugs Market Estimated to Cross US$ 9.8 Bn by 2030

The Veterinary Dermatology Drugs market is projected to grow from USD 3.5 billion in 2020 to reach USD 9.8 billion by 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38531

Veterinary dermatology, also referred as pet skin care, involves diagnosis, treatment, and prevention of skin problems in animals. Dermatological disorders or skin disorders are the most common medical conditions seen in animals. The most common sign of a dermatological problem in animals are licking, biting, repeatedly shaking the head, and excessive scratching or chewing of fur and skin. Additional symptoms of skin problems include lumps, hair loss, dandruff, a foul odor from ears or skin, and change in the texture or color of pet’s fur or skin. Itching is commonly seen in companion animals; atopic dermatitis is the common cause of itching.

According to a research conducted by the Ferdowsi University of Mashhad Veterinary Teaching Hospital, 20% to 40% of small animals suffered from skin problems in Iran in 2013–2014. Globally, this number may be even higher. Variations in clinical presentations such as the extent of lesions, genetic factors, secondary infections, stage of the disease, and weather conditions could complicate the exact diagnosis of the disease. Atopy is genetically determined predisposition to become allergic to airborne pollens such as grass, weeds, trees, mold, and house dust. In domestic pets such as cats and dogs, atopic dermatitis is the most common cause of biting, chewing, rubbing, or ear infections as well as other chronic infections.

Increase in Medical and Diagnostic Capabilities for Companion Animals to Drive Global Market

The global veterinary dermatology drugs market continues to grow at a rapid pace. The market is driven in developed countries by improved diagnostic and medical capabilities for companion animals. There is a rise in the demand for local anesthetics, anti-inflammatory agents, emollients to treat acne, cleansers, and anti-infectives. Moreover, increase in the demand for veterinary and related products such as dairy and agriculture products and rise in awareness about veterinary dermatology drugs are anticipated to drive the global veterinary dermatology drugs market.

Increase in Ownership of Companion Animals to Fuel Market Growth

Rise in companion animal ownership is a significant trend in the animal healthcare segment. In 2013, around 62% of the U.S. households owned a companion animal (excluding horses) i.e., around 72.9 million homes. Brazil, China, India, Mexico, and Russia are among the top countries with a high growth rate in terms of companion animal ownership.

Report Scope

In terms of product type, the global veterinary dermatology drugs market has been classified into antifungal drugs, antibacterial drugs, antiparasitic drugs, and others. The antibacterial drugs segment dominated the global veterinary dermatology drugs market in 2020, owing to high prevalence of bacterial infection among animals and rise in usage of antibacterial drugs.

Based on mode of administration, the global veterinary dermatology drugs market has been categorized into oral, topical, and injectable. The topical segment captured the largest market share in 2020, as it is among the oldest and most efficient mode of administration of drugs to control inflammatory and immune-mediated skin disorders.

In terms of animal type, the global veterinary dermatology drugs market has been bifurcated into large animals and small animals. The large animals segment has been split into equine, bovine, and others. The small animals segment has been segregated into cats, dogs, and others.

Based on indication, the global veterinary dermatology drugs market has been divided into infectious diseases, skin cancer, autoimmune skin diseases, parasitic infections, and others. The infectious diseases segment accounted for significant share of the market in 2020, as infectious diseases are the most common type of veterinary dermatology conditions in companion as well as livestock animals.

In terms of region, North America is projected to be a highly attractive market for veterinary dermatology drugs from 2021 to 2031. High revenue from the region can be attributed to increase in government and private funding and large volume of tests performed. North America is also home to several key players such as Idexx, VCA, and Thermo Fisher, which further propels the market.

The veterinary dermatology drugs market in Asia Pacific is expected to be driven by high adoption of veterinary dermatology drugs, vaccines, and medicated feed additives for the well-being of the rapidly increasing livestock animal population in the region

Key players operating in the global veterinary dermatology drugs market are

    • Merial, Zoetis, Inc.
    • Ceva Sante Animale
    • Vetmedica
    • IDEXX Laboratories
    • Vetoquinol S.A.
    • Virbac S.A.
    • Bayer Animal Health
    • Boehringer Ingelheim
    • Elanco
    • Novartis Animal Health
    • SAVAVET
    • Toray Industries
    • AB Science

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38531

Research Methodology

The research methodology adopted by analysts for compiling the global veterinary dermatology drugs market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global veterinary dermatology drugs market.

Table of Contents

Chapter 1.    Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.    Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.    Executive Summary

3.1.  Market Snapshot

Chapter 4.    Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.     Raw Material Procurement Analysis

4.3.2.     Sales and Distribution Channel Analysis

4.3.3.     Downstream Buyer Analysis

Chapter 5.    Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.     Market Drivers

5.1.2.     Market Restraints

5.1.3.     Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.     Bargaining power of suppliers

5.2.2.     Bargaining power of buyers

5.2.3.     Threat of substitute

5.2.4.     Threat of new entrants

5.2.5.     Degree of competition

Chapter 6.    Competitive Landscape

6.1.1.     Company Market Share/Positioning Analysis

6.1.2.     Key Strategies Adopted by Players

6.1.3.     Vendor Landscape

6.1.3.1.          List of Suppliers

6.1.3.2.          List of Buyers

Chapter 7.    Global Veterinary Dermatology Drugs Market, By Product Type

7.1.  Veterinary Dermatology Drugs Market, by Product Type, 2021-2030

7.1.1.     Antifungal Drugs

7.1.1.1.          Market Revenue and Forecast (2016-2030)

7.1.2.     Antibacterial Drugs

7.1.2.1.          Market Revenue and Forecast (2016-2030)

7.1.3.     Antiparasitic Drugs

7.1.3.1.          Market Revenue and Forecast (2016-2030)

7.1.4.     Others

7.1.4.1.          Market Revenue and Forecast (2016-2030)

Chapter 8.    Global Veterinary Dermatology Drugs Market, By Mode of Administration

8.1.  Veterinary Dermatology Drugs Market, by Mode of Administration, 2021-2030

8.1.1.     Topical

8.1.1.1.          Market Revenue and Forecast (2016-2030)

8.1.2.     Oral

8.1.2.1.          Market Revenue and Forecast (2016-2030)

8.1.3.     Injectable

8.1.3.1.          Market Revenue and Forecast (2016-2030)

Chapter 9.    Global Veterinary Dermatology Drugs Market, By Animal Type

9.1.  Veterinary Dermatology Drugs Market, by Animal Type, 2021-2030

9.1.1.     Large Animals

9.1.1.1.          Market Revenue and Forecast (2016-2030)

9.1.2.     Small Animals

9.1.2.1.          Market Revenue and Forecast (2016-2030)

Chapter 10.Global Veterinary Dermatology Drugs Market, By Indication

10.1.          Veterinary Dermatology Drugs Market, by Indication, 2021-2030

10.1.1.  Infectious Diseases

10.1.1.1.       Market Revenue and Forecast (2016-2030)

10.1.2.  Skin Cancer

10.1.2.1.       Market Revenue and Forecast (2016-2030)

10.1.3.  Autoimmune Skin Diseases

10.1.3.1.       Market Revenue and Forecast (2016-2030)

10.1.4.  Parasitic Infections

10.1.4.1.       Market Revenue and Forecast (2016-2030)

10.1.5.  Others

10.1.5.1.       Market Revenue and Forecast (2016-2030)

Chapter 11.Global Veterinary Dermatology Drugs Market, Regional Estimates and Trend Forecast

11.1.          North America

11.1.1.  Market Revenue and Forecast, by Product Type (2016-2030)

11.1.2.  Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.1.3.  Market Revenue and Forecast, by Animal Type (2016-2030)

11.1.4.  Market Revenue and Forecast, by Indication (2016-2030)

11.1.5.  U.S.

11.1.5.1.       Market Revenue and Forecast, by Product Type (2016-2030)

11.1.5.2.       Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.1.5.3.       Market Revenue and Forecast, by Animal Type (2016-2030)

11.1.5.4.       Market Revenue and Forecast, by Indication (2016-2030)

11.1.6.  Rest of North America

11.1.6.1.       Market Revenue and Forecast, by Product Type (2016-2030)

11.1.6.2.       Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.1.6.3.       Market Revenue and Forecast, by Animal Type (2016-2030)

11.1.6.4.       Market Revenue and Forecast, by Indication (2016-2030)

11.2.          Europe

11.2.1.  Market Revenue and Forecast, by Product Type (2016-2030)

11.2.2.  Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.2.3.  Market Revenue and Forecast, by Animal Type (2016-2030)

11.2.4.  Market Revenue and Forecast, by Indication (2016-2030)

11.2.5.  UK

11.2.5.1.       Market Revenue and Forecast, by Product Type (2016-2030)

11.2.5.2.       Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.2.5.3.       Market Revenue and Forecast, by Animal Type (2016-2030)

11.2.5.4.       Market Revenue and Forecast, by Indication (2016-2030)

11.2.6.  Germany

11.2.6.1.       Market Revenue and Forecast, by Product Type (2016-2030)

11.2.6.2.       Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.2.6.3.       Market Revenue and Forecast, by Animal Type (2016-2030)

11.2.6.4.       Market Revenue and Forecast, by Indication (2016-2030)

11.2.7.  France

11.2.7.1.       Market Revenue and Forecast, by Product Type (2016-2030)

11.2.7.2.       Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.2.7.3.       Market Revenue and Forecast, by Animal Type (2016-2030)

11.2.7.4.       Market Revenue and Forecast, by Indication (2016-2030)

11.2.8.  Rest of Europe

11.2.8.1.       Market Revenue and Forecast, by Product Type (2016-2030)

11.2.8.2.       Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.2.8.3.       Market Revenue and Forecast, by Animal Type (2016-2030)

11.2.8.4.       Market Revenue and Forecast, by Indication (2016-2030)

11.3.          APAC

11.3.1.  Market Revenue and Forecast, by Product Type (2016-2030)

11.3.2.  Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.3.3.  Market Revenue and Forecast, by Animal Type (2016-2030)

11.3.4.  Market Revenue and Forecast, by Indication (2016-2030)

11.3.5.  India

11.3.5.1.       Market Revenue and Forecast, by Product Type (2016-2030)

11.3.5.2.       Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.3.5.3.       Market Revenue and Forecast, by Animal Type (2016-2030)

11.3.5.4.       Market Revenue and Forecast, by Indication (2016-2030)

11.3.6.  China

11.3.6.1.       Market Revenue and Forecast, by Product Type (2016-2030)

11.3.6.2.       Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.3.6.3.       Market Revenue and Forecast, by Animal Type (2016-2030)

11.3.6.4.       Market Revenue and Forecast, by Indication (2016-2030)

11.3.7.  Japan

11.3.7.1.       Market Revenue and Forecast, by Product Type (2016-2030)

11.3.7.2.       Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.3.7.3.       Market Revenue and Forecast, by Animal Type (2016-2030)

11.3.7.4.       Market Revenue and Forecast, by Indication (2016-2030)

11.3.8.  Rest of APAC

11.3.8.1.       Market Revenue and Forecast, by Product Type (2016-2030)

11.3.8.2.       Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.3.8.3.       Market Revenue and Forecast, by Animal Type (2016-2030)

11.3.8.4.       Market Revenue and Forecast, by Indication (2016-2030)

11.4.          MEA

11.4.1.  Market Revenue and Forecast, by Product Type (2016-2030)

11.4.2.  Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.4.3.  Market Revenue and Forecast, by Animal Type (2016-2030)

11.4.4.  Market Revenue and Forecast, by Indication (2016-2030)

11.4.5.  GCC

11.4.5.1.       Market Revenue and Forecast, by Product Type (2016-2030)

11.4.5.2.       Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.4.5.3.       Market Revenue and Forecast, by Animal Type (2016-2030)

11.4.5.4.       Market Revenue and Forecast, by Indication (2016-2030)

11.4.6.  North Africa

11.4.6.1.       Market Revenue and Forecast, by Product Type (2016-2030)

11.4.6.2.       Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.4.6.3.       Market Revenue and Forecast, by Animal Type (2016-2030)

11.4.6.4.       Market Revenue and Forecast, by Indication (2016-2030)

11.4.7.  South Africa

11.4.7.1.       Market Revenue and Forecast, by Product Type (2016-2030)

11.4.7.2.       Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.4.7.3.       Market Revenue and Forecast, by Animal Type (2016-2030)

11.4.7.4.       Market Revenue and Forecast, by Indication (2016-2030)

11.4.8.  Rest of MEA

11.4.8.1.       Market Revenue and Forecast, by Product Type (2016-2030)

11.4.8.2.       Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.4.8.3.       Market Revenue and Forecast, by Animal Type (2016-2030)

11.4.8.4.       Market Revenue and Forecast, by Indication (2016-2030)

11.5.          Latin America

11.5.1.  Market Revenue and Forecast, by Product Type (2016-2030)

11.5.2.  Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.5.3.  Market Revenue and Forecast, by Animal Type (2016-2030)

11.5.4.  Market Revenue and Forecast, by Indication (2016-2030)

11.5.5.  Brazil

11.5.5.1.       Market Revenue and Forecast, by Product Type (2016-2030)

11.5.5.2.       Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.5.5.3.       Market Revenue and Forecast, by Animal Type (2016-2030)

11.5.5.4.       Market Revenue and Forecast, by Indication (2016-2030)

11.5.6.  Rest of LATAM

11.5.6.1.       Market Revenue and Forecast, by Product Type (2016-2030)

11.5.6.2.       Market Revenue and Forecast, by Mode of Administration (2016-2030)

11.5.6.3.       Market Revenue and Forecast, by Animal Type (2016-2030)

11.5.6.4.       Market Revenue and Forecast, by Indication (2016-2030)

Chapter 12.   Company Profiles

12.1.                 Merial, Zoetis, Inc.

12.1.1.  Company Overview

12.1.2.  Product Offerings

12.1.3.  Financial Performance

12.1.4.  Recent Initiatives

12.2.                 Ceva Sante Animale

12.2.1.  Company Overview

12.2.2.  Product Offerings

12.2.3.  Financial Performance

12.2.4.  Recent Initiatives

12.3.                 Vetmedica

12.3.1.  Company Overview

12.3.2.  Product Offerings

12.3.3.  Financial Performance

12.3.4.  Recent Initiatives

12.4.                 IDEXX Laboratories

12.4.1.  Company Overview

12.4.2.  Product Offerings

12.4.3.  Financial Performance

12.4.4.  Recent Initiatives

12.5.                 Vetoquinol S.A.

12.5.1.  Company Overview

12.5.2.  Product Offerings

12.5.3.  Financial Performance

12.5.4.  Recent Initiatives

12.6.                 Virbac S.A.

12.6.1.  Company Overview

12.6.2.  Product Offerings

12.6.3.  Financial Performance

12.6.4.  Recent Initiatives

12.7.                 Bayer Animal Health

12.7.1.  Company Overview

12.7.2.  Product Offerings

12.7.3.  Financial Performance

12.7.4.  Recent Initiatives

12.8.                 Boehringer Ingelheim

12.8.1.  Company Overview

12.8.2.  Product Offerings

12.8.3.  Financial Performance

12.8.4.  Recent Initiatives

12.9.                 Elanco

12.9.1.  Company Overview

12.9.2.  Product Offerings

12.9.3.  Financial Performance

12.9.4.  Recent Initiatives

12.10.              Novartis Animal Health

12.10.1.                   Company Overview

12.10.2.                   Product Offerings

12.10.3.                   Financial Performance

12.10.4.                   Recent Initiatives

12.11.              SAVAVET

12.11.1.                   Company Overview

12.11.2.                   Product Offerings

12.11.3.                   Financial Performance

12.11.4.                   Recent Initiatives

Chapter 13.   Research Methodology

13.1.                 Primary Research

13.2.                 Secondary Research

13.3.                 Assumptions

Chapter 14.   Appendix

14.1.                 About Us

14.2.                 Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38531

Contact Us: 

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com